Experience of intracranial arteriovenous malformations endovascular treatment with advanced techniques and non-adhesive liquid embolic agents using
Abstract
Objective ‒ to evaluate the possibility of endovascular embolization using non-adhesion of liquid embolic agents as monotherapy for the treatment of cerebral arteriovenous malformations (AVM), its reliability and safety.
Materials and methods. examination and gradual endovascular treatment of 64 patients (120 sessions) using non-adhesive liquid embolic agents. Patients were divided into two groups: with ruptured AVM (n = 43) and with unruptured (n = 21). In all cases of unruptured AVM, signs indicating an increased risk of rupture of the AVM were verified.
Results. the average decrease in volume after embolization was 79.5 % (up to 50 % ‒ in 7 cases, 50‒75 % ‒ in 14, 75‒99 % ‒ in 29). Complete exclusion of AVM was achieved in 14 (22 %) patients. On average, 2–3 feeders were embolized on the AVM to achieve such results. It was found that the number of feeders was directly proportional to the number of sessions required. Malformations of small size (up to 3 cm) often managed to close in one session. Clinically significant deficiency (2 on the modified Rankin scale) after embolization was found in 2 (3 %) patients. The deficit regressed within 7 days. The angiographic frequency of complete obliteration of AVM at the end of all embolization procedures was 22 % (14 AVM).
Conclusions. knowledge of the angioarchitectural characteristics of AVM, which are suitable for the treatment with liquid embolic agents, and their careful selection allow to achieve a high frequency of occlusion with a low frequency of complications. The use of superselective intranidal or perinidal positions of the catheter, slow controlled injections that protect the draining veins, the gradual embolization make the therapy safer.
Downloads
References
Bokhari MR, Rizwan S, Bokhari A. Arteriovenous malformation of the brain. N.p., 2019. StatPearls. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28613495
Shaligram Sonali S et al. Risk factors for hemorrhage of brain arteriovenous malformation. CNS Neurosci Ther 2019 Oct;25(10):1085-95. PMCID: PMC6776739 PMID: 31359618 https://doi.org/10.1111/cns.13200
Kim H, Su H, Weinsheimer S, Pawlikowska L, Young WL. Brain arteriovenous malformation pathogenesis: a response‐to‐injury paradigm. Acta Neurochir Suppl. 2011;111:83‐92. PMID: 21725736 PMCID: PMC3187860 https://doi.org/10.1007/978-3-7091-0693-8_14
Stapf C, Mast H, Sciacca RR et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006;66(9):1350‐5. PMID: 16682666 https://doi.org/10.1212/01.wnl.0000210524.68507.87
Mohr JP, Parides MK, Stapf C et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non‐blinded, randomised trial. Lancet. 2014;383(9917):614‐21. PMID: 24268105 PMCID: PMC4119885 https://doi.org/10.1016/S0140-6736(13)62302-8
Baharvahdat H, Blanc R, Fahed R et al. Endovascular treatment for low-grade (Spetzler-Martin I–II) brain arteriovenous malformations. AJNR Am J Neuroradiol. 2019;40:668-72. https://doi.org/10.3174/ajnr.A5988
Cai S, Zhao W, Fan H et al. Endovascular embolization in treatment of brain arteriovenous malformation combined with aneurysms. Chinese Journal of Interventional Imaging and Therapy. 2019;16:8-11.
Hou K, Xu K, Chen X et al. Targeted endovascular treatment for ruptured brain arteriovenous malformations. Neurosurg Rev. 2020 Dec;43(6):1509-18. PMID: 31720915 https://doi.org/10.1007/s10143-019-01205-1
Sato K, Matsumoto Y, Tominaga T et al. Complications of endovascular treatments for brain arteriovenous malformations: A nationwide surveillance. AJNR Am J Neuroradiol. 2020;41:669-75. https://doi.org/10.3174/ajnr.A6470
Alexander MD, Cooke DL, Nelson J et al. Association between venous angioarchitectural features of sporadic brain arteriovenous malformations and intracranial hemorrhage. AJNR Am J Neuroradiol. 2015;36:949-52. https://doi.org/10.3174/ajnr.A4224
Chapot R, Stracke P, Velasco A et al. The pressure cooker technique for the treatment of brain AVMs. J Neuroradiol. 2014;41(1):87-91. https://doi.org/10.1016/j.neurad.2013.10.001.
Asadi H, Kok HK, Looby S, Brennan P, O’Hare A, Thornton J. Outcomes and complications after endovascular treatment of brain arteriovenous malformations: a prognostication attempt using artificial intelligence. World Neurosurg. 2016;96:562-9 e561. https://doi.org/10.1016/j.wneu.2016.09.086
Zuurbier SM, Al-Shahi Salman R. Interventions for treating brain arteriovenous malformations in adults. Cochrane Database Syst Rev. 2019;9:CD003436. https://doi.org/10.1002/14651858.CD003436.pub4
van Rooij WJ, Jacobs S, Sluzewski M et al. Curative embolization of brain arteriovenous malformations with onyx: patient selection, embolization technique, and results. AJNR Am J Neuroradiol. 2012;33:1299-304. https://doi.org/10.3174/ajnr.A2947
Sun Y, Li X, Xiong J, Yu J, Lv X. Transarterial onyx embolization of residual arteriovenous malformation after surgical resection. World Neurosurgery. 2019;126:e1242-5. https://doi.org/10.1016/j.wneu.2019.03.073
Fahed R, Darsaut TE, Mounayer C et al. Transvenous Approach for the Treatment of cerebral Arteriovenous Malformations (TATAM): Study protocol of a randomised controlled trial. Interventional Neuroradiology. 2019;25(3):305-9. https://doi.org/10.1177/1591019918821738
Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65:476-83. PMID: 3760956 https://doi.org/10.3171/jns.1986.65.4.0476
Pasqualin A, Barone G, Cioffi F et al. The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations. Neurosurgery. 1991;28:370-9. PMID: 2011218 https://doi.org/10.1097/00006123-199103000-00006
Hashim H, Muda AS, Abdul Aziz A, Abdul Hamid Z. Onyx in brain arteriovenous malformation embolisation. Malays J Med Sci. 2016;23(4):59-64. https://doi.org/10.21315/mjms2016.23.4.8
This work is licensed under a Creative Commons Attribution 4.0 International License.
